Today, Bio-Works Technologies AB has confirmed a production-scale order worth 3.1 MSEK to an Indian manufacturer of bio-therapeutics. This order is a repeat order from a customer which first started using Bio-Works’ products in 2021.

“Bio-Works prides itself on delivering high-quality products and maintaining strong customer relations. This repeat order is evidence that our efforts to design-in WorkBeads resins in production-scale processes is producing lasting results,” said Jonathan Royce, CEO at Bio-Works.

The company that placed the order is a bio-therapeutics manufacturer with launched products and development projects in the areas of plasma proteins, biosimilars, novel proteins and stem cells therapies. They employee over 1,000 people globally.

The order is confirmed for delivery in the second quarter.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visit www.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-16 14:41 CEST.

Attachments
Bio-Works confirms new order from Indian bio-therapeutic manufacturer worth 3.1 MSEK

© Modular Finance, source Nordic Press Releases